Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphosys Ag ADR (NQ: MOR ) 18.96 UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Morphosys Ag ADR < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting Today 6:15 EDT Via ACCESSWIRE SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders July 17, 2024 From Halper Sadeh LLC Via GlobeNewswire 3 Global Stocks to Buy to Escape the Volatility on Wall Street July 16, 2024 Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times. Via InvestorPlace MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market July 12, 2024 From MorphoSys AG Via Business Wire MorphoSys: Q4 Earnings Insights March 13, 2024 Via Benzinga Earnings Outlook For MorphoSys March 12, 2024 Via Benzinga Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024 March 07, 2024 Via ACCESSWIRE SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders July 08, 2024 From Halper Sadeh LLC Via GlobeNewswire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders June 29, 2024 From Halper Sadeh LLC Via GlobeNewswire MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders June 20, 2024 From Halper Sadeh LLC Via Business Wire MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders June 20, 2024 From MorphoSys AG Via Business Wire Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders June 19, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's After-Market Session May 27, 2024 Via Benzinga MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024 April 30, 2024 MOR stock results show that MorphoSys missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace MorphoSys AG Reports First Quarter 2024 Financial Results April 29, 2024 From MorphoSys AG Via Business Wire MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib April 29, 2024 MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds... Via Benzinga Exposures Product Safety MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting April 24, 2024 Via ACCESSWIRE Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends April 23, 2024 Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. Via Benzinga MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 From MorphoSys AG Via Business Wire MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 Via ACCESSWIRE MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act March 21, 2024 Via ACCESSWIRE MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 13, 2024 From MorphoSys AG Via Business Wire Earnings Scheduled For March 13, 2024 March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. Via Benzinga 5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 March 09, 2024 Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... Via Talk Markets 3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise March 07, 2024 Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. Via InvestorPlace Exit Now! 3 Biotech Stocks to Sell in February 2024 February 21, 2024 These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. Via InvestorPlace Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B February 06, 2024 Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat. Via Benzinga Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion February 05, 2024 Novartis will add to its cancer treatment pipeline with via the German biotech. Via Investor's Business Daily Why Is MorphoSys (MOR) Stock Up 50% Today? February 05, 2024 News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock. Via InvestorPlace Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 05, 2024 Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.